Literature DB >> 18283408

Self-perceived physical functioning and health status among fully ambulatory multiple sclerosis patients.

Maura Pugliatti1, Trond Riise, Monica W Nortvedt, Giovanni Carpentras, M Alessandra Sotgiu, Stefano Sotgiu, Giulio Rosati.   

Abstract

We investigated the self-perceived health status among multiple sclerosis (MS) patients with no or mild disability according to the Expanded Disability Status Scale (EDSS) and the impact of self-rated physical functioning. A sample of fully ambulatory (EDSS < or = 3.5) consecutive patients with MS was included after screening for major cognitive impairment. The EDSS was used to measure nervous system signs or disability, and the self-rated health status was assessed using the SF-36 Health Survey. The normative SF-36 data for the general population of Italy were used for comparison. The 197 MS patients analyzed (150 women and 47 men) had significantly lower mean SF-36 scores than the general population, except for bodily pain. The scores did not differ significantly by gender. The same analysis performed on a subsample of 105 patients (79 women and 26 men) with minimal disability in one functional system (EDSS < or = 2.0) yielded similar results. EDSS was weakly correlated with the physical functioning subscale and explained only 2% of the variance in the physical functioning subscale. The regression of the physical functioning subscale on the other seven SF-36 subscales was significantly lower among MS patients than in the general population for all subscales, except for role limitation due to physical health problems and social functioning. Neither disease course nor duration correlated significantly with SF-36 subscales. The SF-36 physical functioning subscale seemed to indicate physical functioning more sensitively than EDSS. These findings should encourage the implementation of specific strategies aimed at improving the quality of the self-perceived health status already in the early disease stage.

Entities:  

Mesh:

Year:  2008        PMID: 18283408     DOI: 10.1007/s00415-008-0543-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  32 in total

1.  Quality of life as a predictor for change in disability in MS.

Authors:  M W Nortvedt; T Riise; K M Myhr; H I Nyland
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  The factor structure of the SF-36 Health Survey in 10 countries: results from the IQOLA Project. International Quality of Life Assessment.

Authors:  J E Ware; M Kosinski; B Gandek; N K Aaronson; G Apolone; P Bech; J Brazier; M Bullinger; S Kaasa; A Leplège; L Prieto; M Sullivan
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

4.  Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project.

Authors:  J E Ware; B Gandek
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

5.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

6.  Quality of life is favorable for most patients with multiple sclerosis: a population-based cohort study.

Authors:  Sean J Pittock; William T Mayr; Robyn L McClelland; Neal W Jorgensen; Stephen D Weigand; John H Noseworthy; Moses Rodriguez
Journal:  Arch Neurol       Date:  2004-05

7.  Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study.

Authors:  H S J Picavet; N Hoeymans
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

8.  Depressive symptoms account for deficient information processing speed but not for impaired working memory in early phase multiple sclerosis (MS).

Authors:  Nils Inge Landrø; Elisabeth Gulowsen Celius; Helge Sletvold
Journal:  J Neurol Sci       Date:  2004-02-15       Impact factor: 3.181

Review 9.  Clinical outcomes assessment in multiple sclerosis.

Authors:  R Rudick; J Antel; C Confavreux; G Cutter; G Ellison; J Fischer; F Lublin; A Miller; J Petkau; S Rao; S Reingold; K Syndulko; A Thompson; J Wallenberg; B Weinshenker; E Willoughby
Journal:  Ann Neurol       Date:  1996-09       Impact factor: 10.422

10.  Impact of recently diagnosed multiple sclerosis on quality of life, anxiety, depression and distress of patients and partners.

Authors:  A C J W Janssens; P A van Doorn; J B de Boer; F G A van der Meché; J Passchier; R Q Hintzen
Journal:  Acta Neurol Scand       Date:  2003-12       Impact factor: 3.209

View more
  4 in total

1.  Aging with multiple sclerosis: A longitudinal study of physical function, mental health, and memory in two cohorts of US women.

Authors:  Marianna Cortese; Kjetil Bjornevik; Tanuja Chitnis; Alberto Ascherio; Kassandra L Munger
Journal:  Mult Scler       Date:  2021-04-16       Impact factor: 6.312

2.  Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial.

Authors:  Linn H Steffensen; Lone Jørgensen; Bjørn Straume; Svein Ivar Mellgren; Margitta T Kampman
Journal:  J Neurol       Date:  2011-03-13       Impact factor: 4.849

3.  The effect of nurse practitioner (NP-led) care on health-related quality of life in people with multiple sclerosis - a randomized trial.

Authors:  Penelope Smyth; Kaitlyn E Watson; Yazid N Al Hamarneh; Ross T Tsuyuki
Journal:  BMC Neurol       Date:  2022-07-25       Impact factor: 2.903

4.  Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis.

Authors:  Riley Bove; Charles C White; Kathryn C Fitzgerald; Tanuja Chitnis; Lori Chibnik; Alberto Ascherio; Kassandra L Munger
Journal:  Neurology       Date:  2016-09-07       Impact factor: 9.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.